At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 305 enrolled
Drug / intervention
placebo +4 moredrug
Likely dose
PH-797804 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF PH 797804, ADMINISTERED ORALLY ONCE DAILY IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS
In Brief
A Phase 2 clinical trial evaluating placebo and PH-797804 for Arthritis, Rheumatoid. Completed, enrolled 305 participants across 48 sites in 12 countries.
Detailed Summary
Investigating the safety and tolerability of a p38 inhibitor as monotherapy in subjects who have failed at least 1 DMARD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesAustralia, Brazil, Chile, Czechia, Estonia, India, Peru, Poland, Russia, South Africa, South Korea, Spain
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartDec 2006
Primary CompletionJul 2008
Study CompletionJul 2008
TodayJul 2026
First PostedOct 2, 2006
Enrollment StartDec 15, 2006
Primary CompletionJul 1, 2008
Study CompletionJul 16, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.8 years ago
Interventions
placebodrug
Capsule, once daily (QD) for 12 weeks
PH-797804drug
Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
PH-797804drug
Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
PH-797804drug
Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
PH-797804drug
Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks